| Trial | Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS)
ClinicalTrials.gov Identifier: NCT03110432 |
| Aim | Registry study |
| Study design | Prospective observational registry. Patients will receive either standard lipid lowering therapy (statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids and any combinations of these agents), or a PCSK9 inhibitor. The duration of the study is 3 years. |
| Patients | 2000 patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for PCSK9 use, and are treated by office-based cardiologists or in lipid ambulances. |
| Primary outcome | LDL cholesterol goal achievement < 70 mg/dl at 3 years |
| Key results | Ongoing |
| Safety | |
| Author conclusion | |
| Publication | |
| Link | https://clinicaltrials.gov/ct2/show/NCT03110432 |
News
PCSK9 inhibitors benefit high-risk patients with vulnerable plaquesEvolocumab may improve gut health in patients with myocardial infarctionFOURIER: Evolocumab cuts MACE risk in those with obesity and ASCVDAmerican College of Cardiology emphasises PCSK9 inhibitor role for PAD in diabetesUS FDA approves novel PCSK9 inhibitor lerodalcibep for hypercholesterolaemiaStudy sheds light on how PCSK9 promotes LDLR degradation
